Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

XENON PHARMACEUTICALS (XP0.DU)

Dusseldorf - Dusseldorf Delayed Price. Currency in EUR
Add to watchlist
23.40+0.40 (+1.74%)
At close: 08:20AM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close23.00
Open23.40
Bid22.60 x N/A
Ask23.20 x N/A
Day's Range23.40 - 23.40
52 Week Range23.00 - 30.40
VolumeN/A
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Benzinga

    Xenon Pharmaceuticals Insider Sold Over $550K In Company Stock

    Simon Pimstone, Insider at Xenon Pharmaceuticals (NASDAQ:XENE), made a large insider sell on November 15, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Pimstone sold 17,557 shares of Xenon Pharmaceuticals at a price of $31.33. The total transaction amounted to $550,061. Pimstone still owns a total of 210,186 shares of Xenon Pharmaceuticals worth, $6,568,312. Xenon Pharmaceuticals shares are trading down 2.31%

  • GlobeNewswire

    Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

    BURNABY, British Columbia, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Ian Mortimer, Xenon’s President and Chief Executive Officer, along with Sherry Aulin, Xenon’s Chief Financial Officer, will participate virtually in the following investor conferences: Guggenheim 3rd Annual Neuro/Immunology Conference on Monday, November 15, 2021 (one-on-one meetings only)Stifel 2021 Virtual Healthcare Conferen

  • Zacks

    Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Tops Revenue Estimates

    Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 18.18% and 4.69%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Advertisement
Advertisement